BRPI0611670A2 - método para o tratamento ou prevenção de câncer em um indivíduo - Google Patents

método para o tratamento ou prevenção de câncer em um indivíduo

Info

Publication number
BRPI0611670A2
BRPI0611670A2 BRPI0611670A BRPI0611670A BRPI0611670A2 BR PI0611670 A2 BRPI0611670 A2 BR PI0611670A2 BR PI0611670 A BRPI0611670 A BR PI0611670A BR PI0611670 A BRPI0611670 A BR PI0611670A BR PI0611670 A2 BRPI0611670 A2 BR PI0611670A2
Authority
BR
Brazil
Prior art keywords
treating
preventing cancer
individual
methods
inhibiting
Prior art date
Application number
BRPI0611670A
Other languages
English (en)
Inventor
David Y Liu
Stephen J Klauss
Todd W Seeley
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of BRPI0611670A2 publication Critical patent/BRPI0611670A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0611670A 2005-06-15 2006-06-15 método para o tratamento ou prevenção de câncer em um indivíduo BRPI0611670A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69100605P 2005-06-15 2005-06-15
PCT/US2006/023399 WO2006138511A2 (en) 2005-06-15 2006-06-15 Use of hif 1alfa modulators for treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0611670A2 true BRPI0611670A2 (pt) 2016-11-16

Family

ID=37571192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611670A BRPI0611670A2 (pt) 2005-06-15 2006-06-15 método para o tratamento ou prevenção de câncer em um indivíduo

Country Status (13)

Country Link
US (1) US8530404B2 (pt)
EP (1) EP1919463B9 (pt)
JP (2) JP5410751B2 (pt)
KR (1) KR20080028918A (pt)
CN (1) CN101242817B (pt)
AT (1) ATE470439T1 (pt)
AU (1) AU2006259352A1 (pt)
BR (1) BRPI0611670A2 (pt)
CA (1) CA2611785A1 (pt)
DE (1) DE602006014843D1 (pt)
IL (1) IL188101A (pt)
MX (1) MX2007016160A (pt)
WO (1) WO2006138511A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
WO2007090068A2 (en) * 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
EP2016078B1 (en) * 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
US7713986B2 (en) * 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
EP2111399A2 (en) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
ES2446418T3 (es) * 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008137084A2 (en) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2008157177A1 (en) * 2007-06-13 2008-12-24 The Uab Research Foundation Methods for modulating osteoblast cell differentiation and bone generation through inhibition of a prolyl hydroxylase
US8269008B2 (en) * 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20110039879A1 (en) * 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
EP3251671A1 (en) * 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (pt) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
AU2012346899A1 (en) * 2011-12-01 2014-06-19 Cincinnati Children's Hospital Medical Center Materials and methods related to NSAID chemoprevention in colorectal cancer
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US9115085B2 (en) 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9340511B2 (en) 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
WO2014116849A1 (en) 2013-01-24 2014-07-31 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
WO2017040982A1 (en) * 2015-09-02 2017-03-09 The Regents Of The University Of California Her3 ligands and uses thereof
JP6325182B2 (ja) 2015-12-21 2018-05-23 株式会社東京精密 切断用ブレードの製造方法、及び切断用ブレード
CN107115355B (zh) * 2017-05-26 2020-01-17 昆明医科大学 一种含有无机砷化合物的药物组合物及其应用
WO2019138084A1 (en) * 2018-01-11 2019-07-18 Institut Pasteur Phenanthrolinone derivatives for use in the treatment of bacterial infections
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
JP7535285B2 (ja) * 2019-08-02 2024-08-16 公立大学法人大阪 腫瘍関連マクロファージ賦活化剤
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
GB202301059D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
ATE255581T1 (de) 1997-10-24 2003-12-15 Fibrogen Inc Phenanthrolin-derivate
US5916898A (en) 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
JP2001525173A (ja) 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
US6124131A (en) 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
US6506936B1 (en) 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
WO2003045440A1 (en) 2001-11-28 2003-06-05 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein
CN102526045A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
ATE321764T1 (de) 2001-12-19 2006-04-15 Ortho Mcneil Pharm Inc Tetracyclische heteroverbindungen als modulatoren des östrogenrezeptors
GB0211920D0 (en) 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
EP1562970A4 (en) * 2002-11-01 2006-04-12 Univ Pennsylvania COMPOSITIONS AND METHODS FOR SIRNAIL INHIBITION OF HIF-1 ALPHA
US20060276527A1 (en) * 2003-01-17 2006-12-07 Thresold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
WO2006010920A1 (en) 2004-07-30 2006-02-02 Isis Innovation Limited Soluble polypeptide

Also Published As

Publication number Publication date
JP2008543864A (ja) 2008-12-04
CN101242817A (zh) 2008-08-13
HK1117422A1 (en) 2009-02-13
WO2006138511A3 (en) 2007-03-29
DE602006014843D1 (de) 2010-07-22
JP2014012690A (ja) 2014-01-23
EP1919463A2 (en) 2008-05-14
CN101242817B (zh) 2016-08-31
EP1919463B1 (en) 2010-06-09
AU2006259352A1 (en) 2006-12-28
IL188101A (en) 2012-10-31
IL188101A0 (en) 2008-04-13
ATE470439T1 (de) 2010-06-15
MX2007016160A (es) 2008-03-07
US8530404B2 (en) 2013-09-10
KR20080028918A (ko) 2008-04-02
US20070004627A1 (en) 2007-01-04
CA2611785A1 (en) 2006-12-28
JP5410751B2 (ja) 2014-02-05
EP1919463B9 (en) 2011-02-02
WO2006138511A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
WO2006138511A3 (en) Use of hif 1alfa modulators for treatment of cancer
IL258880A (en) Diarylhydantoin compounds
WO2007053573A3 (en) Treatment of cancer with sorafenib
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
ZA200805760B (en) Method for treating disseminated cancer
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
GB0505781D0 (en) Chemical compounds
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
EP1868435A4 (en) COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER
EP1909854A4 (en) METHOD FOR TREATING CANCER
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding
MX2009009693A (es) Metodos para activar irs-1 y akt.
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
TW200716132A (en) Novel chemical compounds
EP1968981A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH AZAXANTHONES
MX2009010954A (es) Actividad antitumoral de temsirolimus en cancer celular renal papilar.
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
TW200716579A (en) Novel chemical compounds
WO2008009895A3 (en) Matriptase-2

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070178322/RJ DE 14/12/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]